TipRanks
Go Ultimate55% OFF

Axon Enterprise (TCS) AI Stock Analysis

DE:TCS

Axon Enterprise

(XETRA:TCS)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Recurring revenue and retentionRapid ARR growth and 126% net revenue retention show that Axon is expanding within its installed customer base, not relying only on new hardware sales. This supports more predictable subscription revenue, stronger customer economics, and durable platform adoption over the coming quarters.
Negative Factors
Uneven operating profitabilityDespite strong revenue and gross-profit growth, operating profitability has not been consistently stable. The prior operating loss and modest trailing net margin indicate that expenses or product mix can absorb substantial revenue gains, creating execution risk for sustained earnings improvement.

Axon Enterprise (TCS) vs. iShares MSCI Germany ETF (EWG)

-60%-50%-40%-30%-20%-10%0%10%20%DE:TCS-37.84%EWG+4.43%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
EUR 34.75B
Dividend Yield
―
Average Volume (3M)
418
Price to Earnings (P/E)
172.3
Beta (1Y)
1.07
Revenue Growth
25.59%
EPS Growth
-46.34%
Country
Germany
Employees
5,100
Sector
Industrials
Sector Strength
63
Industry
Aerospace & Defense

Axon Enterprise Business Overview & Revenue Model

Company Description

Axon Enterprise, Inc., founded in 1993 and headquartered in Scottsdale, Arizona, was previously known as TASER International, Inc. until its rebranding in April 2017. The company specializes in the development, production, and sale of conducted energ...

Axon Enterprise Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|% Change Since:-25.82%|Next Earnings Date:Nov 04, 2026
Earnings Call SentimentPositive

The call conveyed strong, broad-based growth across revenue, software, devices, bookings and international/enterprise markets, with notable product momentum (Dedrone > $100M, TASER 10, Axon Body deployments) and improved profitability metrics. Management raised revenue guidance and highlighted durable metrics (ARR +39%, NRR 126%). Headwinds are present—inventory-driven near-term free cash flow pressure, rising memory/component costs, tariff variability, product-mix impacts, and privacy/governance risks—that could compress margins in Q3 before normalization in Q4. Overall the positives —scale, accelerating software adoption (including AI), bookings momentum and raised guidance—significantly outweigh the transitory operational and mix challenges.

Positive Updates

Record Quarterly Revenue and Strong Top-Line Growth
Revenue of $904 million, up 35% year-over-year; marked the 10th consecutive quarter of growth above 30% and management called it a record quarter.

Negative Updates

Free Cash Flow Near-Term Pressure
Free cash flow was a $1 million outflow in the quarter; management is making substantial inventory investments to support demand and mitigate supply chain risk which is pressuring near-term FCF.

Company Guidance

Axon raised full-year revenue guidance to 32%–34% (up 200 bps from 30%–32%) while reiterating full‑year adjusted EBITDA margin of ~25.5% and a prior free cash flow target of $450M; management expects Q3 adjusted EBITDA to be pressured by higher memory costs with no tariff‑refund benefit, then margins scaling back in Q4 (seasonality similar to last year, with Q4 the strongest quarter). Supporting the outlook, Q2 results and bookings showed strong momentum — revenue $904M (+35% YoY), software & services $398M (+36%), connected devices $507M (+35%), platform solutions $150M (+123%), ARR +39% to $1.6B, NRR 126%, adjusted gross margin 62.9% (+130 bps sequential), adjusted EBITDA $242M (26.8% margin), operating cash flow $20M (vs -$92M prior year), free cash flow outflow $1M, Q2 gross bookings +20% YoY (five‑year normalized bookings +30%+ YoY with line of sight to finish the year in the ~30% range), and future contracted bookings >40% YoY to $15.1B; management also expects body‑camera shipments to rise ~20%–30% sequentially in Q3 (15%–20% q/q) and highlighted Dedrone surpassing $100M in quarterly revenue.

Axon Enterprise Risk Analysis

Axon Enterprise disclosed 51 risk factors in its most recent earnings report. Axon Enterprise reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Axon Enterprise Peers Comparison

Overall Rating

UnderperformOutperform
Sector (63)

Financial Indicators

DE:TCS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
LHXLHX75Outperform$51.69B25.7510.17%1.78%7.33%15.31%
DRSDRS74Outperform$10.05B27.7013.04%0.96%8.85%37.35%
SWBISWBI73Outperform$709.53M24.166.63%3.95%16.96%100.15%
RGRRGR64Neutral$706.24M57.554.29%1.00%7.64%138.23%
Sector *63Neutral$10.79B15.437.44%2.01%2.89%-14.66%
AVAVAVAV54Neutral$6.41B-21.67-6.64%―84.44%-541.91%

* Industrials Sector Average

Performance Comparison

-50%0%50%DE:TCSAVAVLHXDRSSWBIRGRDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
DE:TCS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:TCSAxon Enterprise, Inc.382.30-241.10-38.68%
AVAVAeroVironment, Inc.126.11-241.77-65.72%
LHXL3harris Technologies277.61-6.27-2.21%
DRSLeonardo Drs, Inc.37.681.383.79%
SWBISmith & Wesson Brands, Inc.13.184.3248.69%
RGRSturm, Ruger & Company, Inc.44.203.368.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.